XML 41 R22.htm IDEA: XBRL DOCUMENT v3.24.1
Note 1 - Organization and Summary of Significant Accounting Policies (Details Textual)
12 Months Ended 36 Months Ended
Mar. 08, 2024
USD ($)
$ / shares
Dec. 31, 2023
USD ($)
ft²
shares
Dec. 31, 2022
USD ($)
shares
Aug. 31, 2026
Oct. 05, 2023
USD ($)
Sep. 01, 2023
Number of Operating Segments   1        
Revenue from Contract with Customer, Excluding Assessed Tax   $ 2,898,806 $ 2,930,303      
Accounts Receivable, Allowance for Credit Loss   0 0      
Operating Lease, Expense   72,000 58,000      
Operating Lease, Liability   136,929 0      
Lessee, Operating Lease, Liability, Undiscounted Excess Amount   16,770        
Operating Lease, Right-of-Use Asset   $ 141,439 0      
Operating Lease, Weighted Average Remaining Lease Term (Year)   2 years 8 months 12 days        
Operating Lease, Weighted Average Discount Rate, Percent   8.80%        
Other Income   $ 1,018,000 $ 250,000      
Share-Based Payment Arrangement [Member]            
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) | shares   5,469,247 5,031,097      
The 1044 N Lease [Member]            
Area of Real Estate Property (Square Foot) | ft²   1,719        
Lessee Operating Lease Yearly Percentage Increase       3.00%    
Lessee, Operating Lease, Term of Contract (Year)           3 years
Lessee Operating Lease Additional Number of Renewal Terms           2
Lessee, Operating Lease, Renewal Term (Year)           1 year
Customer Concentration Risk [Member] | Revenue Benchmark [Member]            
Concentration Risk, Number of Customers   16 14      
Concentration Risk, Significant Customers   2 3      
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | Non-US [Member]            
Concentration Risk, Number of Customers   6        
Revenue from Contract with Customer, Excluding Assessed Tax   $ 537,000 $ 586,000      
Concentration Risk, Percentage   21.10% 21.80%      
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | Two Significant Customers [Member]            
Revenue from Contract with Customer, Excluding Assessed Tax   $ 1,150,000        
Concentration Risk, Percentage   45.20%        
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | Three Significant Customers [Member]            
Revenue from Contract with Customer, Excluding Assessed Tax     $ 1,811,000      
Concentration Risk, Percentage     67.50%      
Customer Concentration Risk [Member] | Accounts Receivable [Member]            
Concentration Risk, Number of Customers   13 6      
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Non-US [Member]            
Concentration Risk, Number of Customers   6 4      
Concentration Risk, Percentage   45.60% 27.40%      
Accounts Receivable, after Allowance for Credit Loss   $ 213,000 $ 91,000      
Supplier Concentration Risk [Member] | Contract Research Organizations [Member]            
Concentration Risk, Number of Suppliers   3 3      
Supplier Concentration Risk [Member] | Contract Research Organizations [Member] | Three CROs [Member]            
Concentration Risk, Percentage   96.00% 97.90%      
Research Services Purchased   $ 4,644,000 $ 5,575,000      
Supplier Concentration Risk [Member] | Accounts Payable [Member]            
Concentration Risk, Number of Suppliers   3 3      
Supplier Concentration Risk [Member] | Accounts Payable [Member] | Three CROs [Member]            
Concentration Risk, Percentage   94.40% 79.70%      
Accounts Payable   $ 620,000 $ 1,018,000      
Subsequent Event [Member] | Senior Secured 2024 Notes [Member]            
Debt Instrument, Face Amount $ 6,000,000          
Debt Instrument, Interest Rate, Stated Percentage 8.00%          
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares $ 1.79          
Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger 125.00%          
Inzymes Agreement APS [Member]            
Non-refundable Upfront Payment, Received   600,000     $ 600,000  
Revenue from Contract with Customer, Excluding Assessed Tax   110,000        
Alphazyme [Member]            
Proceeds from Sale, Maturity and Collection of Investments   $ 1,300,000